ArticleEClinicalMedicine2025

Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study.

Zhengfu Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.